Beavers-Gabriel v. Medtronic, Inc.
15 F. Supp. 3d 1021
D. Haw.2014Background
- Plaintiff filed state-law claims against Medtronic related to off-label use of Infuse device in spinal fusion surgery.
- Infuse is a Class III device approved by the FDA for a specific ALIF use; labeling requires the Bone Graft and LT-Cage to be used together.
- FDA PMA approved labeling restricts use to anterior open/anterior laparoscopic approaches at L4–S1 and warns against unapproved indications.
- Plaintiff alleges Medtronic promoted off-label use and concealed adverse information about off-label risks; the device’s labeling and promotion are central to the claims.
- Defendants moved to dismiss on express and implied preemption grounds under MDA, FDCA, and Rule 9(b); the court granted dismissal in part and allowed amendments on some claims.
- Procedural posture culminates in a grant of leave to amend certain counts rather than a complete dismissal.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Preemption scope for off-label promotion claims | Promotion/off-label use claims not preempted per Ramirez approach | Off-label promotion claims preempted or limited under MDA/FDCA | Off-label promotion claims not preempted; but labeling-based claims preempted |
| Preemption of labeling and warning claims | Warnings/labels may parallel federal prohibitions and thus survive | Labeling/warning theories impose new requirements and are preempted | labeling-based failure-to-warn claims preempted; some promotion-based warnings parallelism discussed separately |
| Preemption of design defect claim | Design defect should be judged under state law | Design defect claims require FDA-approved design; preempted | Strict products liability—design defect claim preempted |
| Preemption of negligence and failure-to-report-warnings claims | Claims based on off-label promotion and FDA reporting parallels survive | These claims are impliedly preempted or fail to plead parallel duty | Count V (negligence) impliedly preempted; leave to amend for FDA-reporting-based theory; Count II failure-to-warn preempted; leave for FDA-reporting-based theory |
| Breach of express warranty claim and its preemption | Warranty claims cannot be preempted if based on truthful/voluntary statements | Promotional warranties may be preempted if tied to FDA labeling | Breach of express warranty survives preemption; court allows amendment for alleged false warranties beyond labeling |
| Punitive damages viability | Punitive damages are warranted if underlying claims survive | Punitive damages cannot stand alone without plausible underlying claims | Punitive damages may be pleaded as a remedy in an amended complaint |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (U.S. 2008) (establishes express preemption scope for PMA devices)
- Lohr v. Medtronic, Inc., 518 U.S. 470 (U.S. 1996) (express preemption framework; parallel state duties not preempted)
- Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (U.S. 2001) (implied preemption for fraud-on-the-FDA claims)
- Perez v. Nidek Co., Ltd., 711 F.3d 1109 (9th Cir. 2013) (holds some off-label claims are preempted or allowed based on context)
- Houston v. Medtronic, Inc., 957 F. Supp. 2d 1166 (C.D. Cal. 2013) (off-label promotion claims can survive express preemption when parallel to federal requirements)
- Eidson v. Medtronic, Inc., 981 F. Supp. 2d 868 (N.D. Cal. 2013) (discusses preemption/misbranding and discovery standards in Infuse cases)
- Scovil v. Medtronic, Inc., 995 F. Supp. 2d 1082 (D. Ariz. 2014) (preemption analysis for off-label use and promotion claims)
- Alton v. Medtronic, Inc., 970 F. Supp. 2d 1069 (D. Or. 2013) (preemption for off-label use/promotions context)
- Schouest v. Medtronic, Inc., 13 F. Supp. 3d 692 (S.D. Tex. 2014) (preemption analyses for Infuse components and PMA framework)